Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients
Top Cited Papers
- 16 May 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 226 (12), 2129-2136
- https://doi.org/10.1093/infdis/jiac206
Abstract
It is not known whether sotrovimab, a neutralizing monoclonal antibody (mAb) treatment authorized for early symptomatic coronavirus disease 2019 (COVID-19) patients, is also effective in preventing the progression of severe disease and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant infection. In an observational cohort study of nonhospitalized adult patients with SARS-CoV-2 infection, 1 October 2021–11 December 2021, using electronic health records from a statewide health system plus state-level vaccine and mortality data, we used propensity matching to select 3 patients not receiving mAbs for each patient who received outpatient sotrovimab treatment. The primary outcome was 28-day hospitalization; secondary outcomes included mortality and severity of hospitalization. Of 10 036 patients with SARS-CoV-2 infection, 522 receiving sotrovimab were matched to 1563 not receiving mAbs. Compared to mAb-untreated patients, sotrovimab treatment was associated with a 63% decrease in the odds of all-cause hospitalization (raw rate 2.1% vs 5.7%; adjusted odds ratio [aOR], 0.37; 95% confidence interval [CI], .19–.66) and an 89% decrease in the odds of all-cause 28-day mortality (raw rate 0% vs 1.0%; aOR, 0.11; 95% CI, .0–.79), and may reduce respiratory disease severity among those hospitalized. Real-world evidence demonstrated sotrovimab effectiveness in reducing hospitalization and all-cause 28-day mortality among COVID-19 outpatients during the Delta variant phase.Keywords
Funding Information
- National Center for Advancing Translational Sciences
- National Institutes of Health (UL1TR002525, UL1TR002535-03S3, UL1TR002535-04S2)
This publication has 25 references indexed in Scilit:
- Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort CollaborativeJAMA Network Open, 2021
- Early Experience With Neutralizing Monoclonal Antibody Therapy For COVID-19Published by Cold Spring Harbor Laboratory ,2021
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19The New England Journal of Medicine, 2021
- Optimizing the Trade-off Between Learning and Doing in a PandemicJAMA, 2020
- Firth's logistic regression with rare events: accurate effect estimates and predictions?Statistics in Medicine, 2017
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- A Tutorial and Case Study in Propensity Score Analysis: An Application to Estimating the Effect of In-Hospital Smoking Cessation Counseling on MortalityMultivariate Behavioral Research, 2011
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009
- Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal InferencePolitical Analysis, 2007
- A solution to the problem of separation in logistic regressionStatistics in Medicine, 2002